InnoCare Pharma Ltd
SSE:688428
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (41.6), the stock would be worth ¥32.4 (14% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 36.4 | ¥28.38 |
0%
|
| Industry Average | 41.6 | ¥32.4 |
+14%
|
| Country Average | 28.8 | ¥22.46 |
-21%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥19B
|
/ |
Jan 2026
¥499.7m
|
= |
|
|
¥19B
|
/ |
Dec 2026
¥203.7m
|
= |
|
|
¥19B
|
/ |
Dec 2027
¥72.3m
|
= |
|
|
¥19B
|
/ |
Dec 2028
¥532.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
InnoCare Pharma Ltd
SSE:688428
|
24B CNY | 36.4 | 37.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 14 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 11.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 20.7 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 40.2 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 10.5 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
InnoCare Pharma Ltd
Glance View
InnoCare Pharma Ltd., a beacon in the bustling world of biotech, epitomizes the fusion of scientific innovation and entrepreneurial vision. Born out of the relentless pursuit to tackle some of the world's most challenging diseases, the company is primarily focused on developing and commercializing novel therapies for cancer and autoimmune diseases. Founded in China, InnoCare leverages its robust research and development network to explore new frontiers in drug discovery, making targeted therapies that aim to meet significant unmet medical needs. The company thrives at the intersection of cutting-edge biotechnology and meticulous clinical trials, bridging the gap between complex scientific data and patient well-being. The business model of InnoCare Pharma revolves around the creation and commercialization of proprietary drug candidates. Revenue streams flow from strategic partnerships, licensing agreements, and ultimately, the sale of its innovative pharmaceutical products. By maintaining a synergistic blend of internal research efforts and external collaborations, InnoCare not only fortifies its pipeline of drug candidates but also expands its global footprint. Their flagship product, often leading the charge from theory to the shelves of hospitals, underscores the company’s commitment to transforming promising scientific research into tangible, life-saving treatments. Through successful navigation of regulatory processes and strategic market entry, InnoCare solidifies its position not just as a pharmaceutical creator, but as a catalyst for hope in combating severe health conditions.
